Voximetry received 510(k) market clearance from the U.S. Food and Drug Administration for its Torch Dose Assessment for Radiopharmaceutical Therapy, the company announced recently.

According to a release, Torch can provide estimates of absorbed radiation dose following internal administration of approved radiopharmaceuticals.

“As the accuracy leader, Torch is the best tool to demonstrate the importance of heterogenous, density corrected, dosimetric assessments,” Voximetry CEO Sue Wallace said in a statement. “This is an important first step on the path to accurate personalized treatments that may include increased tumor response or improved protection for critical organs.”

The Torch is now available for clinical implementation nationwide.